Evidence map›Paper›PMID 26464496›Full record

ArticleJournal of oncology practice2015

Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.

Sandra E Brooks, Carolyn Y Muller, William Robinson, Eleanor M Walker, Kate Yeager, Elise D Cook, Sue Friedman, Carol P Somkin, Carol Leslie Brown, Worta McCaskill-Stevens

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Participant-Centered Strategies for Overcoming Barriers to Biospecimen Collection among Spanish-Speaking Latina Breast Cancer Survivors.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sandra E BrooksCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD sandraebrooks40@aol.com.
Carolyn Y MullerCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
William RobinsonCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Eleanor M WalkerCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Kate YeagerCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Elise D CookCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Sue FriedmanCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Carol P SomkinCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Carol Leslie BrownCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.
Worta McCaskill-StevensCompleteCare Health Network, Bridgeton, NJ; University of New Mexico, Albuquerque, NM; Tulane University, New Orleans, LA; Henry Ford Hospital, Detroit, MI; Emory University, Atlanta, GA; University of Texas MD Anderson Cancer Center, Houston, TX; Facing Our Risk of Cancer Empowered, Tampa, FL; Kaiser Permanente, Oakland, CA; Memorial Sloan Kettering Cancer Center, New York, NY; and National Cancer Institute, Bethesda, MD.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180822NCI NIH HHS U10CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U10CA180868
6 · The paper itself

Abstract

Racial and ethnic diversity has historically been difficult to achieve in National Cancer Institute-sponsored clinical trials, even while as many as 80% of those trials have faced difficulty in meeting overall recruitment targets. In an attempt to address these issues, NRG Oncology recently convened a comprehensive workshop titled "Clinical Trials Enrollment: Challenges and Opportunities." Discussants at the workshop included representatives of the three legacy groups of the NRG (ie, Gynecologic Oncology Group, National Surgical Adjuvant Breast and Bowel Program, and Radiation Therapy Oncology Group), a minority-based community clinical oncology program, a large integrated health care system, the leadership of the National Cancer Institute, and a large patient advocacy group. This article summarizes the concepts discussed at the workshop, which included: needs assessments, infrastructural support, training of investigators and research staff, specific clinical trial recruitment strategies (both system and community based), and development and mentoring of young investigators. Many new, more specific tactics, including use of diverse cancer care settings, direct-to-consumer communication, and the need for centralized information technology such as the use of software to match trials to special populations, are presented. It was concluded that new, innovative trial designs and the realities of limited funding would require the adoption of effective and efficient recruiting strategies, specialized training, and stakeholder engagement. US clinical research programs must generate and embrace new ideas and pilot test novel recruitment strategies if they are to maintain their historic role as world leaders in cancer care innovation and delivery.

Indexed as

Clinical Trials as TopicMinority GroupsBiomedical ResearchEducationHumansMedical Oncology

Identifiers

PMID26464496
PMCPMC5706134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.